AbbVie has announced a new $380-million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. The facilities are the first in AbbVie’s previously announced plan to invest $100 billion in US R&D and manufacturing over the next 10 years. 

The new facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie’s neuroscience and obesity medications. 

Construction will begin in spring 2026, with both new facilities expected to be fully operational in 2029. To support these new facilities, AbbVie plans to hire 300 people in North Chicago, including engineers, scientists, manufacturing operators and lab technicians. 

In addition to its planned investments in Illinois, AbbVie recently announced plans to acquire a device-manufacturing facility in Arizona and to make investments at its manufacturing facility in Massachusetts. The company says it is currently in discussions with multiple US states about potential manufacturing investments and anticipates announcing additional investments in 2026. 

Source: AbbVie